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Abstract
The introduction of molecular diagnostic methods is crucial for improved understanding of the aetiology and epidemiology
of bacterial infections in communities in resource poor settings. A blood sample from a 7 month old patient diagnosed with
malaria in 2001 in a Gambian outpatient clinic was reported as culture negative after it was subjected to traditional bacterial
culture protocols. We re-addressed the analysis of the blood sample from this case more recently (after 6.5 years in archival
storage) in pilot work establishing 16S rRNA PCR in our molecular laboratory. Initial 16S rRNA PCR results confirmed the
presence of bacterial DNA in the sample. 16S rRNA sequence analysis identified the organism as Campylobacter spp. In light
of the molecular evidence we successfully grew the organism using appropriate culture conditions and subsequently
biochemically confirmed that the isolate was Campylobacter jejuni. PCR and DNA sequencing of a set of seven C. jejuni
housekeeping genes and in silico Multilocus Sequence Typing (MLST) analysis revealed that the isolate exhibits a novel
sequence type (ST) of C. jejuni (ST 2928) and belongs to ST-443 clonal complex. This study demonstrates the potential for
molecular tools to enhance the diagnosis of bacterial infections, which remain a major killer globally, not least in children in
the developing world. Improvements in diagnostics are needed, and will be important not only for sick individuals but also
for populations, where better measures of disease burden will contribute significantly to the improvement of public health
policy.
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Introduction
The emergence of opportunistic pathogens in immunocompro-
mised hosts, such as HIV-infected patients, has increased the
burden on clinical diagnostic laboratory services in developing
countries. Reliable and accurate identification of these pathogens
poses a serious challenge, necessitating the widening of the scope
of the assays traditionally employed in resource poor settings.
Traditional bacterial culturing techniques have many deficiencies,
necessitating a search for adjunctive or alternative approaches
such as molecular protocols. Errors in identifying poorly described,
rarely isolated, or phenotypically aberrant bacterial strains are
likely to be common in routine clinical diagnostic laboratories
using traditional culturing and biochemical methods exclusively.
Traditional bacterial culturing protocols rely on replicating in
vitro the physical and biochemical requirements of each bacterial
species. The traditional culturing methods are limiting by
definition, e.g. in a mixed microbial population specific culture
media may enrich for a single bacterial species, while a distinct
species with distinct physical and metabolic requirements will not
be detected despite being present in the sample. The limitations of
traditional bacterial culturing technologies have been highlighted
by the low culture success rate from samples taken at foci of
infection, e.g. lung aspirate samples in pneumonia patients [1].
Molecular methods have many advantages over traditional
protocols employed for identification and characterization of
bacteria in clinical samples, reviewed [2,3]. Molecular protocols
have the potential to rapidly identify the aetiological agents of
unexplained, culture-negative illnesses or to resolve or better
characterize ‘overlap’ clinical syndromes facilitating more appro-
priate and more directed therapy. Molecular protocols may play
an important role in epidemiological studies where failure of
culture-dependent methods to detect low level bacterial carriage
compromises the study of changes in microbial ecology in patients
following vaccination.
‘Broad-range’ 16S rRNA PCR and DNA sequencing have
emerged as potential adjunctive tools or as alternative culture-
independent methods for detecting and identifying pathogenic
bacteria in clinical samples. Organism specific MLST analysis
allows more definitive identification of bacterial isolates providing
useful epidemiological data for identifying the source and course of
outbreaks. The extensive and rapidly growing internet based 16S
rRNA and MLST databases facilitate rapid identification of
sequences to the species or genus level. The advantages and
caveats associated with this broad range PCR approach have been
reviewed elsewhere [4–5]
‘Overlap’ syndromes, where different diseases are difficult to
distinguish clinically, create a challenge for both health workers
and health systems, especially in resource-poor countries. This is
particularly so in malaria endemic settings where clinical
symptoms of malaria are practically indistinguishable from those
of pneumonia and can compromise the process of case
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range of molecular tools applied to an archival blood sample
followed by the utilization of internet bioinformatic resources
helped to characterize a novel ST of C. jejuni in the Gambia.
Our results make a strong case for the routine use of molecular
techniques, which if applied prudently can play a vital role
in clinical diagnosis and monitoring of antibacterial therapy,
while retaining cost effectiveness in resource poor developing
countries.
Methods
Informed written consent was obtained as described elsewhere
[7]. The study and all protocol revisions were approved by the
ethics committees of the Gambia Government/MRC, the London
School of Hygiene and Tropical Medicine and by the WHO
Secretariat Committee for Research Involving Human Subjects.
Forty seven clinical samples (all lung aspirate and venous blood)
from 33 patients were retrieved from our archives; these samples
had been stored from this previous study [7]. These samples were
selected for a pilot study, undertaken to establish 16S rRNA PCR in
our molecular laboratory. Samples were blinded on assignment of
a laboratory number before being processed in batches for DNA
extraction and 16S rRNA PCR. Two of the blood samples (sample
numbers 2 and 3) in addition to being positive for 16S rRNA PCR
showed unusual eletrophoretic shifts on agarose gel eletrophoresis,
relative to the expected size of the PCR products (see results
section below). This aroused our suspicion that the samples might
contain unusual bacterial species, and it was on this basis that we
pursued these samples for further molecular characterisation. Lack
of availability of MLST PCR and sequencing primers, however,
restricted our molecular characterisation of the bacterium present
to just one of these blood samples, sample number 2, which is
highlighted in this case report.
The patient behind the sample
A whole blood sample had been taken from a 7 month old girl
recruited in 2001 as part of a previously described study [7]. The
child presented with a several day history of cough, fever and
diarrhoea and was not on any medication at the time of
assessment. She appeared sick, had a temperature of 39.3uC and
had a raised respiratory rate of 46 per minute without signs of
severe respiratory distress. A blood film showed a significant
Plasmodium falciparum parasitaemia (200 parasites per high-powered
field). She was admitted to hospital with a diagnosis of malaria,
and treated according to local guidelines with chloroquine and
pyrimethamine-sulfadoxine. A blood culture taken on admission
was reported as negative. She was discharged after 2 days having
made a good recovery.
A blood sample from this case was retried from archival storage
(280uC for 6.5 years) and examined by molecular methods for the
presence of bacterial DNA as part of a molecular pilot study, as
indicated above.
Extraction of DNA from the sample
100 ml of each of the archival blood samples was added to
180 ml of lysozyme buffer (20 mM Tris-HCl, 2mM EDTA, 1.2
% Triton X-100, 20 mg/ml lysozyme (Sigma)) for 30 min at
37uC. Proteinase K (25 ml) was added and the sample incubated
at 70uC for 30 min. The sample was subjected to the standard
Qiagen DNA Mini Kit (Qiagen Ltd. UK) extraction protocol
with 2625 ml elutions on the same column using the kit elution
buffer. The DNA eluate was stored at 220uC prior to 16S rRNA
PCR.
16S rRNA standard PCR conditions
Each 25 ml 16S rRNA PCR reaction contained 17.5 mlo f
molecular biology-grade water (Sigma Aldrich Company Ltd.),
2.5 mlo f1 0 6PCR buffer (Qiagen Ltd.), 1 ml of 12.5 mM each
forward and reverse PCR primers, 1 ml of a 10 mM dNTPs
(Invitrogen Ltd.), 0.25 mlo fTaq DNA polymerase (Qiagen Ltd.),
and 2 ml of DNA extracted from the clinical sample. Non-template
control (NTC) samples contained the same PCR reagents as above
but had 2 ml of water substituted for template. The positive control
was a local isolate of Streptococcus pneumoniae. PCR amplification
conditions on an MJ thermocycler were as follows: 94uC for
10 min, followed by 25 cycles of 94uC for 30 s, 60uC for 1 min,
and 72uC for 1 min, with a final extension at 72uC for 10 min and
storage at 4uC.
MLST was performed as follows
Seven PCR amplicons were prepared from purified DNA
extracted from a glycerol stock of the bacterial isolate by using the
PCR primers shown in Table 1. Each 25 ml PCR mixture was
identical to the 16S rRNA PCR above, except for the primers and
2 ml of purified C. jejuni DNA as template. The amplification
conditions were 94uC for 10 min, followed by 35 cycles of 94uC
for 30 s, 50uC for 1 min, and 72uC for 1 min, with a final
extension at 72uC for 10 min and storage at 4uC. Non-template
control (NTC) samples contained the same reagents as above for
each of the 7 distinct PCR reactions but had 2 ml of water
substituted for template in each case.
All 16S rRNA PCR, MLST PCR and DNA sequencing
oligonucleotide primers were obtained from Sigma Genosys
(Table 1).
Agarose gel electrophoresis
All standard 16S rRNA PCR and C. jejuni specific MLST PCR
products were assessed for expected PCR product size on 2 % (w/
v) agarose gels with a 100 bp DNA ladder (New England Biolabs).
Aliquots of PCR products were electrophoresed at 150V for
45 min; DNA was visualized using ethidium bromide and
photographed after UV transillumination with PD-Quest 7.3.1
basic 2D analysis software (Bio-Rad).
16S rRNA and MLST gene sequencing
16S rRNA and C. jejuni specific MLST PCR products were sent
to Macrogen in South Korea (http://www.macrogen.com) for
purification and DNA sequencing. For primers used in PCR and
sequencing reactions see Table 1:
Bioinformatic applications
All forward and reverse sequences were aligned for each
amplicon using the ClustalW program to assess the specificity of
the sequencing reactions (http://www.ebi.ac.uk/clustalw/). Re-
verse sequences were reverse complemented (http://bioinfor-
matics.org/sms/rev_comp.html) prior to alignment using Clus-
talW.
All sequence data was subjected to BLAST analysis (non-
redundant nucleotide sequence database search) (http://www.
ncbi.nlm.nih.gov/BLAST/) to definitively identify each respective
16S rRNA and MLST gene amplicon.
MLST alleles and sequence types were assigned to the isolate by
comparing data to the Campylobacter MLST database (http://
campylobacter.mlst.net). Data for the newly described alleles and
STs were deposited in the Campylobacter MLST database http://
pubmlst.org/campylobacter/. All resulting gene sequences from
this study were deposited in Genbank (Table 1).
Novel Campylobacter Isolate
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analysis of C. jejuni from the sample
A2 5ml aliquot of the archival blood sample was inoculated and
streaked on Campylobacter-selective agar plates Columbia agar (cat
# Oxoid CM 0331) prepared aseptically with supplement (Oxoid
SR0098E) in 10% sheep blood agar. The cultured plate was
incubated in a microbiological culture jar, 10% CO2, 5% Oxygen
and 85% Nitrogen, achieved using a Campy-gas generating kit
(cat # Oxoid BR0060A) and a palladium catalyst. The jar was
closed tightly and incubated for 48 hrs at 42uC. Isolates were
biochemically characterized using Oxidase cytochrome (N,N,N –
Tetramethyl-P-Phenylenediamine dihydrochloride) (Sigma), Cat-
alase (Riedel-de Haen) and Ninhydrin (BactiDrop Ninhydrin,
Remel) tests were all carried out for definitive and differential
biochemical characterization.
Results
16S rRNA PCR and sequencing analysis
Of the first batch of six archival clinical sample gDNA extracts,
only two were positive for bacterial DNA by 16S rRNA PCR,
sample 2 and 3 (Figure 1), these samples represented venous
blood samples from 2 distinct patients. Samples 1, 4, 5 and 6
tested negative for bacterial DNA. The gel mobility shift of the
16S rDNA band from the archival blood samples 2 and 3 were
visibly distinct in size from the positive control (Streptococcus
pneumoniae). This observation is based on an expected amplicon
size of 466 bp from PCR primers designed to generate products
between nucleotide residues 331 and 797 of the Escherichia coli 16S
rRNA gene [8]. The non-template control samples were negative
and the positive control sample was positive as expected.
Sequencing of the 16S rRNA PCR products resulted in clear,
clean sequence traces for both forward and reverse reactions from
sample 2 and 3. There was 100% alignment agreement for
forward and reverse sequencing traces for each sample using the
ClustalW sequence alignment program. This indicated that rather
than a mixed bacterial population, one major organism was
present in each of the samples. In silico BLAST analysis of the 16S
rRNA sequence data for sample 2 indicated a 100% homology
with the NCTC 11168 C. jejuni [9]. Sample 3 was identified by
BLAST analysis of the sequencing data as Trichococcus spp (96%
homology), [EU418263]. We did not attempt to culture the
Trichococcus spp, as there was only sufficient sample to do a gDNA
extraction for 16S rRNA PCR but not for culture work.
Molecularly the Trichococcus spp. was not further characterized
due to the lack of specific MLST PCR and sequencing primers
for this organism.
MLST of the Campylobacter jejuni isolate
Six of the seven C.jejuni specific MLST genes were successfully
amplified by PCR; the fifth tkt (transketolase) failed initial PCR
amplification but was successfully PCR amplified and sequenced
using the sequencing primers in a nested approach (Figure 2). All
7 MLST house keeping genes were successfully sequenced in both
directions in duplicate, using a direct and nested sequencing
approach (Genbank accession numbers EU056829 to EU056835).
High quality sequence traces were obtained for all 7 products from
both the forward and reverse sequencing reactions and from the
nested reactions. ClustalW alignment indicated 100% agreement
between forward and reverse reaction sequencing products for all
7 MLST C.jejuni specific MLST genes. Sequences resulting from
the standard and nested reactions were in 100% agreement.
Submission of the MLST sequence data for all 7 house keeping
genes to the campylobacter MLST database, indicated that while
all 7 alleles had been described individually previously, they had
not been described in the combination that we found. Thus the
Table 1. MLST alleles, GenBank accession numbers, PCR and sequencing primers (59 to 39) for blood samples No. 2 & 3.
Gene MLST Allele Genbank PCR Forward 59-39 PCR Reverse 59-39
aspA 24 EU056829 AGTACTAATGATGCTTATCC ATTTCATCAATTTGTTCTTTGC
glnA 2 EU056830 TAGGAACTTGGCATCATATTACC TTGGACGAGCTTCTACTGGC.
gltA 2 EU056831 GGGCTTGACTTCTACAGCTACTTG CCAAATAAAGTTGTCTTGGACGG
glyA 15 EU056832 GAGTTAGAGCGTCAATGTGAAGG AAACCTCTGGCAGTAAGGGC
pgm 294 EU056833 GCAAACTCAGGACACCCAGG AAAGCATTGTTAATGGCTGC
tkt 3 EU056834 GCTTAGCAGATATTTTAAGTG AAGCCTGCTTGTTCTTTGGC
uncA 12 EU056835 ATGGACTTAAGAATATTATGGC ATAAATTCCATCTTCAAATTCC.
C. jejuni 16S rRNA N/A EU056828 TCCTACGGGAGGCAGCAGT GGACTACCAGGGTATCTAATCCTGTT
Tricococcus sp. 16S rRNA N/A EU418263 TCCTACGGGAGGCAGCAGT GGACTACCAGGGTATCTAATCCTGTT
Gene MLST Allele Genbank Sequencing Forward 59-39 Sequencing Reverse 59-39
aspA 24 EU056829 CCAACTGCAAGATGCTGTACC TTCATTTGCGGTAATACCATC.
glnA 2 EU056830 CATGCAATCAATGAAGAAAC TTCCATAAGCTCATATGAAC
gltA 2 EU056831 CTTATATTGATGGAGAAAATGG CCAAAGCGCACCAATACCTG
glyA 15 EU056832 AGCCTAATTCAGGTTCTCAA AGGTGATTATCCGTTCCATCGC
pgm 294 EU056833 GGTTTTAGATGTGGCTCATG TCCAGAATAGCGAAATAAGG
tkt 3 EU056834 GCTTAGCAGATATTTTAAGTG AAGCCTGCTTGTTCTTTGGC
uncA 12 EU056835 AAAGTACAGTGGCACAAGTGG TGCCTCATCTAAATCACTAGC
C. jejuni 16S rRNA N/A EU056828 TCCTACGGGAGGCAGCAGT GGACTACCAGGGTATCTAATCCTGTT
Tricococcus sp. 16S rRNA N/A EU418263 TCCTACGGGAGGCAGCAGT GGACTACCAGGGTATCTAATCCTGTT
All amplicons from C.jejuni isolate unless stated otherwise.
doi:10.1371/journal.pone.0001773.t001
Novel Campylobacter Isolate
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in the literature or the database. The novel ST was designated ST-
2928: With an allele profile code; 24, 2, 2, 15, 294, 3, 12, for aspA,
glnA, uncA, glyA, pgm, tkt, and gltA respectively. The isolate is a
member of the previously described C.jejuni clonal complex ST-
443 also isolated and identified in humans [10].
Bacterial Culture
Culturing an aliquot of the clinical archival sample number 2
under optimum culture conditions for C. jejuni (in light of the 16S
rRNA data) resulted in florid bacterial growth with morphological
characteristics typical of C.jejuni. Colonies from the isolate were
identified as Gram-negative rods, and biochemically characterized
asoxidase,catalaseandninhydrinpositiveallconsistentwithC.jejuni.
Discussion
We have discovered a novel C.jejuni isolate in The Gambia (ST-
2928) using a molecular based approach as an adjunct to
traditional culture and biochemical characterisation protocols.
Traditional bacterial culture protocols had failed to isolate the
organism in a blood sample when the patient first presented
6.5 years previously; hence the discovery was made as a direct
consequence of using molecular protocols. There was no history of
treatment with antimicrobials before admission to account for the
negative blood culture. Rather, inappropriate incubation of the
blood sample at 37uC as opposed to 42uC may explain why the
organism was not detected originally in the patient’s blood sample.
The laboratory however, had no a priori reason to consider
culturing this patient’s blood sample at 42uC when the patient first
presented. The optimum temperatures for most bacteria that are
pathogenic to humans are 35uC–37uC, and hence the tempera-
tures most frequently used to culture organisms in a clinical
diagnostic laboratory. Although Campylobacter species are not
difficult to isolate per se, they do require special media, special
temperature and atmospheric conditions for growth [11]. C.jejuni is
grown on especially selective agar plates at 42uC, the normal avian
body temperature (which constitutes an important source and
natural reservoir of the organism). When more appropriate culture
conditions were applied, after initial 16S rRNA sequencing
identified the organism in the sample, we obtained florid culture
growth, sufficient numbers of bacteria for optimal biochemical
testing, and sufficient quantities of DNA for successful MLST
analysis of the C.jejuni isolate.
Figure 1. 2 % agarose gel, 16S rRNA PCR of gDNA extracted from archival blood samples 1 to 6. 2 ml of gDNA in 25 ml PCR reaction with
256PCR cycles. 5 ml loaded on gel. Image is reverse colour under UV transillumination (Bio-Rad). Positive control (+Control) used 2 ml of gDNA from a
local Streptococcus pneumoniae isolate. Non template control (NTC) consisting of 25 ml PCR mix only, water control 2 ml molecular grade water in
place of gDNA.
doi:10.1371/journal.pone.0001773.g001
Figure 2. 2 % agarose gel, PCR of gDNA extracted from a C. jejuni isolate using both PCR and sequencing oligonucleotide primers
for C.jejuni MLST genes 1 to 7. 2 ml extracted gDNA used in 25 ml PCR reaction with 356PCR cycles. 3 ml loaded on gel. Image is reverse colour
under UV tranillumination (Bio-Rad). NTC=Non-template control, 3 ml of each individual reaction combined and 21 ml loaded on gel.
doi:10.1371/journal.pone.0001773.g002
Novel Campylobacter Isolate
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DNA sequencing and MLST analysis to an archival blood sample
from a complex clinical case, which was reported as culture
negative for bacterial growth after original presentation. The
recent completion of the sequencing of the C. jejuni genome
(NCTC11168) has greatly facilitated advances in molecular based
detection and characterization of this pathogen and important
public health burden [9]. C. jejuni is a member of the delta-epsilon
group of proteobacteria and is Gram-negative, flagellate, curved
or spiral, microaerophilic and motile. C. jejuni is the leading cause
of bacterial food-borne diarrhoeal disease throughout the world
[12] and has been reviewed elsewhere [13]. It has also been
described as an important cause of diarrhoeal illness in African
children under 5 years of age [14–16]. Campylobacter jejuni has been
divided into two subspecies: C. jejuni subsp. jejuni and C. jejuni subsp.
doylei. Almost all of the C. jejuni strains isolated are C. jejuni subsp.
jejuni. Although subspecies doylei strains are isolated only rarely,
they differ from subsp. jejuni in two important aspects: they are
obtained mainly from human clinical samples and are associated
more often with bacteraemia [17].
To study the epidemiology of Campylobacter infections, multiple
typing methods have been developed [18]. The MLST method
was developed by Dingle et al, to characterize C. jejuni strains and
to identify clonal lineages in this species [19–20,10,21–22]. This
method uses genetic variations at multiple chromosomal locations
and allows generation of sequence data, which are deposited in
internet databases for comparison with DNA sequences of other
isolates.
Despite its accuracy, 16S rRNA gene sequence analysis lacks
widespread use beyond the large and reference laboratories
because of technical and cost considerations, this may be a
confounding issue in developing countries such as The Gambia
where technological and financial resources are limited. Thus, a
future challenge is to incorporate 16S rRNA gene sequencing into
routine protocols in concert with traditional microbiological and
biochemical testing. The availability of free internet based
molecular bioinformatic tools such as search engines and
databases for molecular analysis represents a great resource for
laboratories within developing countries, using or planning to use
molecular protocols in their work.
Amplification and sequencing of the 16S rRNA has become the
method of choice for ‘broad-range’ identification of bacterial
species in clinical samples or cultures but for more definitive
characterization it is necessary to complete organism specific
MLST analysis, and this was the rationale behind our approach in
this case. It has been suggested that the clinical interpretation of
‘broad-range’ 16S rRNA PCR and sequencing results can be
problematical e.g. the protocol has the potential to detect all
bacterial DNA present in a given clinical sample, including non-
viable or even degraded organisms. A background level of
bacterial DNA might be present in blood of patients without
any overt clinical signs of bacteraemia [23–24]. The consequences
of detection of bacterial DNA in blood in so called ‘healthy’
patients has not been adequately addressed to date. An important
caveat to these observations is that low levels of bacterial nucleic
acids may be due to contamination of reagents and equipment
acquired in the process of sample collection and processing or
transient bacteraemia. Contamination, however miniscule, has the
potential to significantly reduce the sensitivity of the molecular
protocols, if not adequately addressed. Contamination is not an
issue in the current case as a high load of C. jejuni was observed
without any trace of 16S rDNA in the non-template controls (See
Figure 1).
While molecular test results are less subjective than those from
traditional microbiological/biochemical characterization proto-
cols, it would be premature to advocate replacement of the
traditional culture protocols at this juncture with molecular
technology. Molecular protocols may however act as an important
adjunct to traditional culturing. It may be useful to incorporate the
routine use of molecular protocols such as 16S rRNA PCR and
sequencing as an initial screen for microbial pathogens in clinical
samples, this would allow more selective and efficient use of
traditional culturing for confirmation, the cost of the molecular
methods being offset by using less traditional culture associated
consumables. Overall, gene amplification and DNA sequencing
from culture and clinical material may improve our understanding
of microbial pathogenesis and better predict responses to therapy
and clinical outcome; they may also provide much needed insight
into the complex ecology of mixed infections in vivo.
More broadly molecular methods such as these have potentially
important clinical and public health applications. From the clinical
point of view, key diagnostic possibilities for this patient included
serious bacterial infection (including pneumonia, infective diar-
rhoea, septicaemia), and malaria. In this case the diagnoses were
two: there was clear evidence for malaria but the co-existing
bacteraemia was missed. While this child recovered from her
bacteraemia without specific treatment (though possibly assisted
unintentionallybythe sufadoxinecontainedinhermalariatherapy),
invasive bacterial disease, often unrecognised, is a major killer of
children in Africa and globally and improvements in diagnostics are
urgently needed to improve outcomes (Mulholland and Adegbola
2005 [25]. This case indicates that molecular methods can improve
diagnosis when used in concert with traditional methodologies. A
key challenge is to establish more widespread use of molecular
protocols in developing world settings. Such advances will be
important not only at the bedside but at the population level where
better measures of disease burden will contribute significantly to the
improvement of public health policy.
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